A Quantitative Metal-Encoded Conjugate Platform for Targeting Ligand Discovery

Area of Science:

• Biomedical Engineering
• Nanomedicine
• Pharmacology

Background:

• Indiscriminate biodistribution of therapeutics limits drug safety and efficacy, causing toxic effects in non-diseased tissues.
• Nanomedicine utilizes targeting agents for localized drug delivery, but a limited number of effective agents exist.
• Small-molecule ligands offer advantages as targeting agents due to cost, tunability, and conjugation ease, yet systematic discovery methods are lacking.

Purpose of the Study:

• To develop a quantitative metal-encoded conjugate platform for in vivo biodistribution analysis of multiple small molecules.
• To establish a systematic approach for discovering novel small-molecule targeting ligands.
• To accelerate the identification of new biological targets for precise tissue-targeted drug delivery.

Main Methods:

• Development of a quantitative metal-encoded conjugate platform utilizing lanthanide metal complexes.
• In vivo administration of the platform to assess biodistribution of small molecules.
• Distinguishing differential tissue targeting of known ligands using the developed system.

Main Results:

• The platform successfully determined the biodistribution of multiple small molecules in vivo.
• Lanthanide metal complexes enabled the differentiation of known ligands with distinct tissue targeting profiles.
• Demonstrated the feasibility of using the platform for in vivo small molecule tracking.

Conclusions:

• The quantitative metal-encoded conjugate platform facilitates the discovery of small molecules as effective targeting ligands.
• This system accelerates the identification of novel biological targets for improved tissue-targeted drug delivery.
• Overcomes limitations in current targeting agent discovery for nanomedicine applications.